Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Inclusion Criteria: * Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma (tFL), or high-grade B-cell lymphoma (HGBCL), at least 2 prior lines of systemic therapy * Planned to receive standard of care therapy with axicabtagene ciloleucel * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Measurable disease of \>= 1.5 cm * At least two weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for axicabtagene ciloleucel (axi-cel) therapy, except for systemic immune checkpoint inhibitory / immune stimulatory therapy. At least 3 half-lives must have elapsed from any prior systemic immune checkpoint inhibitory / immune stimulatory therapy at the time the subject is planned for leukapheresis (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists, etc) * Toxicities due to prior therapy must be stable and recovered to =\< grade 1 (except for clinically non-significant toxicities such as alopecia) * Absolute neutrophil count of \>= 1.0 x 10\^9/L * Platelet count of \>= 60 x 10\^9/L * Creatinine clearance (as estimated by Cockcroft Gault) \>= 45 mL/minute (min) * Serum alanine transaminase (ALT) / aspartate transaminase (AST) =\< 2.5 upper limit of normal (ULN) * Total bilirubin =\< 1.5 mg/dL, except in subjects with Gilbert's syndrome * Cardiac ejection fraction \>= 50%…